Nesiritide

Generic Name: Nesiritide

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 124584-08-3

Unique Ingredient Identifier: P7WI8UL647

Background: Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide.

Indication: 适用于急性代偿性心力衰竭、慢性失代偿性心力衰竭、心肌梗死、心脏导管手术等。由于静脉使用起效快，更适用于急性心力衰竭。

Associated Conditions: Acute Decompensated Heart Failure (ADHF)

Associated Therapies: -

Clinical Trials

Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure

Phase 1

Terminated

Conditions: Cardiorenal Syndrome

Interventions: Drug: Nesiritide

First Posted Date: 2006-07-04

Last Posted Date: 2017-11-06

Lead Sponsor: Horng Chen

Target Recruit Count: 4

Registration Number: NCT00348556

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest

Phase 3

Completed

Conditions: Heart Failure, Congestive
Heart Decompensation

Interventions: Drug: nesiritide

First Posted Date: 2006-02-08

Last Posted Date: 2011-06-10

Lead Sponsor: Scios, Inc.

Target Recruit Count: 127

Registration Number: NCT00288730

Nesiritide Use Following Cardiac Surgery in Infants

Phase 1

Terminated

Conditions: Cardiopulmonary Bypass
Heart Defects, Congenital

Interventions: Drug: Placebo
Drug: nesiritide

First Posted Date: 2006-01-25

Last Posted Date: 2020-08-27

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 9

Registration Number: NCT00281671

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels

Phase 3

Completed

Conditions: Heart Failure, Congestive
Heart Decompensation

First Posted Date: 2006-01-02

Last Posted Date: 2011-03-04

Lead Sponsor: Scios, Inc.

Target Recruit Count: 305

Registration Number: NCT00271557

Renal Effects of Intrarenal Nesiritide

Phase 4

Terminated

Conditions: Heart Failure, Congestive

Interventions: Drug: nesiritide

First Posted Date: 2005-12-28

Last Posted Date: 2019-12-23

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 2

Registration Number: NCT00270829

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States

FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.

Phase 3

Completed

Conditions: Heart Failure, Congestive

Interventions: Drug: nesiritide
Drug: usual long term cardiac medications

First Posted Date: 2005-12-26

Last Posted Date: 2011-07-26

Lead Sponsor: Scios, Inc.

Target Recruit Count: 214

Registration Number: NCT00270361

A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.

Phase 3

Completed

Conditions: Symptomatic Decompensated Congestive Heart Failure
Congestive Heart Failure in Acute Coronary Syndrome

Interventions: Drug: nesiritide

First Posted Date: 2005-12-26

Last Posted Date: 2011-06-10

Lead Sponsor: Scios, Inc.

Target Recruit Count: 498

Registration Number: NCT00270374

A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure

Phase 3

Completed

Conditions: Heart Failure, Congestive

Interventions: Drug: nesiritide

First Posted Date: 2005-12-26

Last Posted Date: 2011-06-10

Lead Sponsor: Scios, Inc.

Target Recruit Count: 255

Registration Number: NCT00270400

Catheterization Laboratory Study: Acute Responses in Diastolic Heart Failure

Not Applicable

Completed

Conditions: Heart Failure, Congestive

First Posted Date: 2005-09-20

Last Posted Date: 2019-02-08

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 15

Registration Number: NCT00204945

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure

Phase 3

Completed

Conditions: Kidney Diseases
Congestive Heart Failure
Cardiomyopathy

First Posted Date: 2005-09-15

Last Posted Date: 2009-11-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 104

Registration Number: NCT00170183

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy